Bluejay Diagnostics, Inc.
BJDXNasdaq
$1.45
↑ +11.5%Jul 17 close · end-of-day
Price
1Y↓ -77.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.4M
Enterprise Value
-$2.3M
P/E
—
P/S
—
P/B
0.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$6.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-165.1%
ROIC
-1113.7%
Debt / Equity
—
Net Cash
$3.7M
Return 1Y
-77.5%
Company profile
Bluejay Diagnostics, Inc. develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis.
- CEO
- Indranil Dey
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 9
- Headquarters
- Massachusetts
- Website
- bluejaydx.com
Earnings
BJDX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.95↓ -85.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $249,040.00 | — | — | — |
| Gross profit | — | — | $48,911.00 | — | — | — |
| Operating income | -$1.2M | -$3.2M | -$9.3M | -$10.3M | -$7.2M | -$7.0M |
| Net income | -$1.2M | -$3.5M | -$9.3M | -$10.0M | -$7.7M | -$6.8M |
| Diluted EPS | — | -$0.41 | -$9.22 | -$3,631.48 | -$456.75 | -$15.25 |
| Operating cash flow | -$508,710.00 | -$4.4M | -$7.7M | -$8.3M | -$7.8M | -$6.1M |
| Free cash flow | — | -$4.4M | -$8.9M | -$9.0M | -$8.1M | -$6.2M |
| Gross margin | — | — | 19.6% | — | — | — |
| Operating margin | — | — | -3741.5% | — | — | — |
| Net margin | — | — | -3733.1% | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.9M | -$1.4M | -$1.5M | -$1.9M | -$2.0M | -$1.6M | -$1.5M | -$1.9M |
| Net income | -$2.5M | -$1.5M | -$1.4M | -$1.9M | -$2.0M | -$1.6M | -$1.4M | -$1.9M |
| Diluted EPS | -$256.16 | -$76.94 | $271.11 | -$13.46 | -$1.41 | -$1.01 | $0.63 | -$1.95 |
| Operating cash flow | -$1.9M | -$2.2M | -$1.5M | -$1.2M | -$2.1M | -$1.4M | -$1.5M | -$1.6M |
| Free cash flow | -$2.2M | -$2.2M | -$1.5M | — | — | — | — | -$1.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 2, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-10 | HRT FINANCIAL LLC | Sale | 34,938 | $1.40 | $48,913.20 | filing |
| 2026-07-09 | HRT FINANCIAL LLC | Buy | 64,047 | $1.51 | $96,710.97 | filing |
| 2026-03-14 | Wurth Douglas Clark | Buy | 12,500 | $2.00 | $25,000.00 | filing |
| 2026-03-14 | Dey Indranil· President and CEO | Buy | 12,500 | $2.00 | $25,000.00 | filing |
| 2026-03-14 | CHASE DONALD R | Buy | 12,500 | $2.00 | $25,000.00 | filing |
| 2026-03-14 | ZEIDMAN FRED S | Buy | 12,500 | $2.00 | $25,000.00 | filing |
| 2026-03-14 | Dey Svetlana | Buy | 12,500 | $2.00 | $25,000.00 | filing |
Latest 7 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.